Danaher Corporation (DHR) is showing signs of recovery after a challenging period post-COVID-19, during which its stock lagged significantly behind the broader market. Despite a staggering 52,700% return since its inception in 1969, shares are currently 36% below their all-time high, raising questions about the stock’s future. The company, a leader in life sciences, faced a revenue decline as pandemic-related demand normalized and sales from China weakened.
However, Danaher recently announced a significant $9.9 billion acquisition of Masimo, a pulse oximetry technology leader, which is expected to enhance its diagnostics portfolio and contribute over $530 million in EBITDA by 2027. With a current price-to-earnings ratio of just over 22, well below its historical average of 32, and strong first-quarter earnings growth of 9.5%, Danaher presents an attractive buying opportunity for investors looking for value in the healthcare sector.
For professionals in the market, Danaher’s potential for earnings growth and strategic acquisitions could signal a turnaround, making it a stock to watch closely.
Source: fool.com